NEW YORK – Cure51 on Wednesday said it has raised €15 million ($16.3 million) in seed funding to study extended survival in patients with highly aggressive cancers such as metastatic pancreatic cancer and glioblastoma.
Sofinnova Partners led the round with participation from Hitachi Ventures GmbH, Life Extension Ventures, and individual investors including Xavier Niel and Datadog CEO Olivier Pomel.
Paris-based Cure51 was founded in March 2022 with a mission to create a global clinical and molecular database of cancer survivors. The company hopes that by studying "exceptional" cancer survivors instead of disease mechanisms only, it can uncover processes contributing to prolonged survival and incorporate them into treatments for all cancer patients.
In a statement, the company said it is seeking to unlock mechanisms of survival "to enable every patient to become an exceptional survivor with new insights for precision medicine and drug target discovery."
"Modern AI models require world class datasets to uncover novel biology and discover transformative medicines, and this is what Cure51 is uniquely creating for cancer patients," said Joanna Soroka, principal at Hitachi Ventures GmbH.